313471-11-3

Basic information

• Product Name: ethyl 2-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)acetate
• Synonyms: ethyl 2-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)acetate
• CAS NO: 313471-11-3
• Molecular Formula: C₁₇H₁₈O₅
• Molecular Weight: 302.32182
• Mol File: 313471-11-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 477.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• CAS DataBase Reference: ethyl 2-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)acetate(313471-11-3)
• EPA Substance Registry System: ethyl 2-((6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy)acetate(313471-11-3)

Safety Data

• Hazardous Substances Data: 313471-11-3(Hazardous Substances Data)

Upstream product

• 3722-44-9 3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one 
• 105-39-5 chloroacetic acid ethyl ester 
• 108-46-3 recorcinol 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 105-36-2 ethyl bromoacetate 
• 1139-83-9 urolithin B 

Downstream Products

• 325737-63-1 2-[(7,8,9,10-tetrahydro-6-oxo-6H-dibenzo[b,d]pyran-3-yl)oxy]acetic acid 

Relevant articles and documents

Modified coumarins. 5. Amino-acid derivatives of 3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one

Peptide-chemistry methods (symmetric anhydrides and activated esters) and the Mannich reaction were used to prepare various conjugates of amino acids with 7,8,9,10-tetrahydrobenzo[c]chromen-6-one in which the amino acids are bound to the coumarin by the C- or N-terminus.

Synthesis of Fluorescent Probes Targeting Tumor-Suppressor Protein FHIT and Identification of Apoptosis-Inducing FHIT Inhibitors

For the early diagnosis of cancer, leading to a better chance of full recovery, marker genes whose expression is already altered in precancerous lesions are desirable, and the tumor-suppressor gene FHIT is one candidate. The gene product, FHIT protein, has a unique dinucleoside triphosphate hydrolase (AP3Aase) activity, and in this study, we designed and synthesized a series of FHIT fluorescent probes utilizing this activity. We optimized the probe structure for high and specific reactivity with FHIT and applied the optimized probe in a screening assay for FHIT inhibitors. Screening of a compound library with this assay identified several hits. Structural development of a hit compound afforded potent FHIT inhibitors. These inhibitors induce apoptosis in FHIT-expressing cancers via caspase activation. Our results support the idea that FHIT binders, no matter whether inhibitors or agonists of AP3Aase activity, might be promising anticancer agents.